Dickens Theodore serves as Vice President, Clinical Development at GSK. He leads the clinical development of bepirovirsen, an investigational antisense oligonucleotide for the treatment of chronic hepatitis B virus infection. His experience in the pharmaceutical industry spans multiple therapeutic areas, early clinical research and late phase development. Prior to joining GSK, he was an assistant professor of medicine at the University of North Carolina School of Medicine, Chapel Hill in the Division of Gastroenterology and Hepatology and the Division of Infectious Diseases.